Passage Bio, Inc. (PASG)
| Market Cap | 14.19M -41.9% |
| Revenue (ttm) | n/a |
| Net Income | -36.11M |
| EPS | -11.31 |
| Shares Out | 3.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,063 |
| Open | 4.350 |
| Previous Close | 4.440 |
| Day's Range | 4.300 - 4.470 |
| 52-Week Range | 3.290 - 20.000 |
| Beta | 1.43 |
| Analysts | Buy |
| Price Target | 15.50 (+251.47%) |
| Earnings Date | Aug 10, 2026 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PASG stock is "Buy." The 12-month stock price target is $15.5, which is an increase of 251.47% from the latest price.
News
Passage Bio Quarterly report: Q2 2026
Passage Bio has published its Q2 2026 quarterly earnings report on August 10, 2026.
Passage Bio Slides: Investor presentation
Passage Bio has posted slides in relation to its latest quarterly earnings report, which was published on July 22, 2026.
Passage Bio Transcript: M&A announcement
A merger will create a publicly traded RNA therapeutics company with a strong clinical pipeline and over $100 million in new funding. Passage shareholders will own about 7% of the combined entity, with the deal expected to close in Q4 2026 and cash runway into 2028.
Passage Bio Press release: M&A announcement
Passage Bio issued a press release on June 24, 2026, disclosing material business information to investors.
Passage Bio, Remix Therapeutics to combine in all-stock transaction
Passage Bio (PASG) and Remix Therapeutics announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon completion of the transaction, the combined c...
Passage Bio trading halted, news pending
16:01 EDT Passage Bio (PASG) trading halted, news pending
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin
Guggenheim downgrades Passage Bio to Neutral, terminates coverage
Guggenheim analyst Debjit Chattopadhyay downgraded Passage Bio (PASG) to Neutral from Buy without a price target while subsequently terminating coverage of the name. The company initiated a review of ...
Passage Bio downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Passage Bio (PASG) to Neutral from Buy with no price target
Passage Bio Transcript: AGM 2026
The meeting covered board elections, ratification of the accounting firm, and executive compensation votes. All proposals passed, including annual advisory votes on executive pay. No questions were raised by stockholders during the Q&A.
Passage Bio Quarterly report: Q1 2026
Passage Bio has published its Q1 2026 quarterly earnings report on May 12, 2026.
Passage Bio Slides: Corporate presentation
Passage Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Wedbush downgrades Passage Bio to Neutral on regulatory uncertainties
As previously reported, Wedbush analyst Yun Zhong downgraded Passage Bio (PASG) to Neutral from Outperform with a price target of $8, down from $32. The firm cites Monday’s regulatory update…
Passage Bio downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Yaron Werber downgraded Passage Bio (PASG) to Hold from Buy with no price target after the company released updated Phase 1/2 frontotemporal dementia with granulin mutations data…
Passage Bio price target lowered to $15 from $30 at Oppenheimer
Oppenheimer lowered the firm’s price target on Passage Bio (PASG) to $15 from $30 and keeps an Outperform rating on the shares after the company released upliFT-D data alongside FDA…
Passage Bio downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Passage Bio (PASG) to Neutral from Outperform with a price target of $8, down from $32.
Passage Bio downgraded to Neutral from Buy at Chardan
Chardan analyst Janani Sundararajan downgraded Passage Bio (PASG) to Neutral from Buy with a $7 price target following the company’s decision to pursue strategic alternatives. The firm sees uncertaint...
Passage Bio downgraded to Neutral from Buy at Lucid Capital
Lucid Capital analyst Elemer Piros downgraded Passage Bio (PASG) to Neutral from Buy with a price target of $9, down from $68, after the company reported updated data from the…
Passage Bio reports updated interim data from upliFT-D trial
Passage Bio (PASG) reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia, FTD, with granulin mutations. In addition, t...
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
Passage Bio Slides: Corporate presentation
Passage Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 17, 2026.
Passage Bio Proxy statement: Proxy filing
Passage Bio filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Passage Bio Proxy statement: Proxy filing
Passage Bio filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Passage Bio initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Passage Bio (PASG) with an Outperform rating and $30 price target. The firm views the year-to-date pullback in shares as “an overreaction” to competitor program failu...